Home Antibody All anti-IL17A antibodies
Anti-IL17A Antibody Polyclonal
Also for IL17A (NM_002190)
|E.coli derived Recombinant Human IL-17 (IL-17A) |
||Lot dependent; please refer to CoA along with shipment
|WB, ELISA, IHC
|A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.|
|Produced from sera of goats pre-immunized with highly pure (>98%) recombinant hIL-17A. Anti-Human IL-17A specific antibody was purified by affinity chromatography employing immobilized hIL-17 matrix.
|Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of Human IL-17A (50.00 ng/ml), a concentration of 0.43 ? 0.65 ug/ml of this antibody is required.
|Homo sapiens interleukin 17A (IL17A)|
|CTLA8; IL-17; IL-17A; IL17|
Entrez Gene 3605 Human
|Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.|
Cytokine-cytokine receptor interaction
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
To detect hIL-17A by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-17A is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
To detect hIL-17A by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human IL-17A (60-017AGBT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-17A.
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.125 ug/ml - 0.25 ug/ml with an overnight incubation at 4C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary. Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute.